Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men.

Abstract

INTRODUCTION:

Hypogonadism is defined as decreased testosterone levels in men. Hypogonadism can be accompanied by erectile, orgasmic, and ejaculatory dysfunction.

AIMS:

To evaluate whether treatment with testosterone solution 2% (testosterone) could improve ejaculatory function in a cohort of hypogonadal men.

METHODS:

Sexually active, hypogonadal men at least 18 years old (total testosterone < 300 ng/dL) were randomized to receive testosterone or placebo for 12 weeks.

MAIN OUTCOME MEASURES:

Effects of testosterone on primary outcomes were evaluated using the International Index of Erectile Function (IIEF) and the Men's Sexual Health Questionnaire, Ejaculatory Dysfunction, Short Form (MSHQ-EjD-SF) questionnaires. Treatment differences were calculated using analysis of covariance.

RESULTS:

In total, 715 men (mean age = 55 years) were randomized to placebo (n = 357) or testosterone (n = 358). Most sexually active men who reported IIEF scores had some degree of erectile dysfunction (IIEF erectile function score < 26). Although ejaculatory function score (MSHQ-EjD-SF) improved in the testosterone group compared with placebo (P < .001), improvement on the "bother" item did not reach statistical significance. Treatment-related adverse events in the testosterone group affecting at least 1% of patients were increased hematocrit, upper respiratory tract infection, arthralgia, burning sensation, fatigue, increased prostate-specific antigen, erythema, and cough. Few patients in either treatment group developed at least one adverse event leading to discontinuation (testosterone = 1.98% vs placebo = 3.09%; P = .475).

CONCLUSION:

Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.

• Authors: Mario Maggi, Darell Heiselman, Jack Knorr, Smriti Iyengar, Darius A Paduch, Craig F Donatucci
• Journal: The journal of sexual medicine (J Sex Med) Vol. 13 Issue 8 Pg. 1220-6 (08 2016) ISSN: 1743-6109 [Electronic] Netherlands
• PMID: 27436077 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Copyright © 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Chemical References

• Androgens
• Testosterone
• Prostate-Specific Antigen

Topics

• Adult
• Aged
• Androgens (administration & dosage)
• Drug Administration Schedule
• Ejaculation (drug effects)
• Erectile Dysfunction (drug therapy)
• Humans
• Hypogonadism (drug therapy)
• Male
• Men's Health
• Middle Aged
• Orgasm (drug effects)
• Penile Erection (drug effects)
• Prostate-Specific Antigen (metabolism)
• Sexual Behavior (physiology)
• Surveys and Questionnaires
• Testosterone (administration & dosage)
• Treatment Outcome